GW 273225

Drug Profile

GW 273225

Alternative Names: GW273225

Latest Information Update: 19 Dec 2013

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antiepileptic drugs; Neuropsychotherapeutics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bipolar disorders; Epilepsy

Most Recent Events

  • 19 Dec 2013 Discontinued - Phase-I for Epilepsy in United Kingdom (PO)
  • 19 Dec 2013 Discontinued - Phase-I for Bipolar disorders in United Kingdom (PO)
  • 31 Mar 2007 Phase-I clinical trials in Epilepsy (in healthy volunteers) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top